We are live on
!
Find out more
T
TOBAM Portfolio holdings
AUM
$412M
1-Year Est. Return
18.33%
This Fund
S&P 500
This Quarter
Est. Return
-7.74%
1 Year Est. Return
+18.33%
3 Year Est. Return
+56.05%
5 Year Est. Return
+49%
10 Year Est. Return
+255.15%
AUM
$1.6B
AUM Growth
-$392M
(-20%)
Cap. Flow
-$203M
Cap. Flow
% of AUM
-12.69%
Top 10 Holdings %
Top 10 Hldgs %
25.61%
Holding
503
New
74
Increased
178
Reduced
101
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Quest Diagnostics
DGX
|
+$24.5M |
| 2 |
Church & Dwight Co
CHD
|
+$19.6M |
| 3 |
Eversource Energy
ES
|
+$18.2M |
| 4 |
Expedia Group
EXPE
|
+$17.6M |
| 5 |
Kimberly-Clark
KMB
|
+$17.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$31.2M |
| 2 |
Conagra Brands
CAG
|
+$27M |
| 3 |
SEE
Sealed Air
SEE
|
+$22.8M |
| 4 |
Eli Lilly
LLY
|
+$22.1M |
| 5 |
Regency Centers
REG
|
+$20.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 28% |
| 2 | Consumer Staples | 25.89% |
| 3 | Communication Services | 10.3% |
| 4 | Technology | 7.09% |
| 5 | Materials | 6.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Agnico Eagle Mines
AEM
$104B
| $20.6M | 1.29% |
451,104
+29,767
| +7% | +$1.66M |
|
|
PARA
27
DELISTED
Paramount Global Class B
PARA
| $20.6M | 1.29% |
834,280
+429,752
| +106% | +$13.1M |
|
28
Baxter International
BAX
$13.4B
| $20.4M | 1.28% |
318,233
+78,755
| +33% | +$5.72M |
|
29
Lumen
LUMN
$6.98B
| $20M | 1.25% |
1,830,931
-587,943
| -24% | -$6.6M |
|
30
Verizon
VZ
$208B
| $19M | 1.19% |
374,660
-18,149
| -5% | -$918K |
|
31
Kroger
KR
$35.9B
| $19M | 1.19% |
401,103
-115,948
| -22% | -$6.18M |
|
|
32
Gilead Sciences
GILD
$187B
| $18.5M | 1.16% |
298,970
-504,021
| -63% | -$31.2M |
|
|
33
Conagra Brands
CAG
$7.43B
| $18.1M | 1.13% |
527,706
-791,441
| -60% | -$27M |
|
34
Dentsply Sirona
XRAY
$2.27B
| $17.5M | 1.1% |
490,734
+268,631
| +121% | +$10.9M |
|
|
35
Eversource Energy
ES
$26.8B
| $17.5M | 1.1% |
207,051
+204,541
| +8,149% | +$18.2M |
|
36
SolarEdge
SEDG
$2.1B
| $16.5M | 1.04% |
60,365
+31,406
| +108% | +$8.59M |
|
37
Domino's
DPZ
$11.3B
| $16.1M | 1.01% |
41,383
-36,015
| -47% | -$13.3M |
|
38
EOG Resources
EOG
$76.2B
| $15.1M | 0.94% |
136,278
+6,685
| +5% | +$830K |
|
39
Rogers Communications
RCI
$20.3B
| $15M | 0.94% |
313,652
+43,651
| +16% | +$2.28M |
|
40
Take-Two Interactive
TTWO
$40.1B
| $14.7M | 0.92% |
119,659
+68,046
| +132% | +$8.66M |
|
41
EPAM Systems
EPAM
$6.04B
| $13.9M | 0.87% |
47,047
+27,269
| +138% | +$8.33M |
|
42
SLB Ltd
SLB
$85.3B
| $13.8M | 0.86% |
385,216
+325,502
| +545% | +$13.6M |
|
43
Humana
HUM
$48.2B
| $13.4M | 0.84% |
28,651
+17,851
| +165% | +$7.94M |
|
44
Wheaton Precious Metals
WPM
$70.4B
| $13.2M | 0.83% |
366,828
-130,791
| -26% | -$5.68M |
|
45
Cboe Global Markets
CBOE
$31.2B
| $12.8M | 0.8% |
113,068
-75,238
| -40% | -$8.45M |
|
46
Burlington
BURL
$16.7B
| $12.3M | 0.77% |
89,945
+59,015
| +191% | +$10.7M |
|
47
Snap
SNAP
$9.25B
| $12.1M | 0.76% |
919,133
+334,336
| +57% | +$7.62M |
|
|
48
Expedia Group
EXPE
$35.8B
| $11.8M | 0.74% |
+124,451
| New | +$17.6M |
|
49
Lucid Motors
LCID
$1.84B
| $10.8M | 0.68% |
63,159
+8,841
| +16% | +$1.68M |
|
50
Regeneron Pharmaceuticals
REGN
$85.2B
| $10.6M | 0.67% |
18,014
-18,663
| -51% | -$12.1M |
|
Similar funds
EC
WIP
KP
MP
AWP
THCM
PA
HP
TOBAM's Q2 2022 Portfolio in Review
As of Q2 2022, TOBAM held 503 positions worth $1.6B, down 20% from $1.99B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
TOBAM withdrew a net $203M in Q2 2022, closing 74 positions and reducing 101 holdings. Its most notable exit was Novavax, an estimated $12.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 26% a quarter earlier, followed by Consumer Staples and Communication Services.
Against the trend, TOBAM opened a new position in Expedia Group worth $11.8M.
- TOBAM's largest Q2 2022 buy was Expedia Group: 124,451 shares worth $11.8M.
- TOBAM added most to Quest Diagnostics in Q2 2022, an estimated $24.5M increase.
- TOBAM's biggest Q2 2022 reduction was Gilead Sciences, cutting an estimated $31.2M.
- TOBAM fully exited Novavax in Q2 2022, selling an estimated $12.8M.
- TOBAM's ten largest holdings make up 26% of its $1.6B portfolio in Q2 2022.
- TOBAM opened 74 new positions and closed 74 in Q2 2022.
- TOBAM's portfolio value fell 20% quarter-over-quarter to $1.6B.
Based on TOBAM's 13F filing for Q2 2022, filed 2 Aug 2022.